(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed ...

Human immunodeficiency virus (HIV) is a virus that attacks the body's immune system. HIV is a manageable chronic condition. With treatment, people living with HIV can have long and healthy lives.

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV on Black communities. | Since 1999, Feb. 7 has marked National Black ...

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...